SEC Form 4 · accession 0001209191-15-016911
ImmunoCellular Therapeutics, Ltd. · IMUC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Anthony Gringeri
Officer — Senior VP Strategic Resources
Period of report
Feb 18, 2015
Accepted (ET)
Feb 20, 2015 · 6:38 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000822411
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 18, 2015 | P | 30,000 | $0.60 | A | 66,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Warrant to Purchase Common StockF1 | $0.66 | Feb 18, 2015 | P | 21,000 | A | Feb 18, 2015 | Feb 18, 2020 | Common Stock | 21,000 | 21,000 | D |
Explanation of responses
- F1Purchase price is the price paid for one share of common stock and 0.70 of a warrant to purchase one share of common stock.